Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib

(2020) Gianluigi Giannelli et al.   PLoS One

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Andrew X Zhu et al.   LANCET ONCOLOGY

Ramucirumab and the controversial role of α-fetoprotein in hepatocellular carcinoma

(2019) Ghassan K Abou-Alfa   LANCET ONCOLOGY

Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib ( LY 2157299) in Advanced Hepatocellular Carcinoma

(2019) Sandrine Faivre et al.   LIVER INTERNATIONAL

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models

(2019) Heng Sheng Sow et al.   Cells

Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma

(2019) Jian Chen et al.   TRENDS IN MOLECULAR MEDICINE

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

(2019) R.K. Kelley et al.   Clinical and Translational Gastroenterology

Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

(2019) Valeria Santini et al.   CLINICAL CANCER RESEARCH

Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study

(2019) M.M. Tibben et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model

(2018) Seddik Hammad et al.   ARCHIVES OF TOXICOLOGY

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

(2018) Julius Strauss et al.   CLINICAL CANCER RESEARCH

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

(2018) Rikke B. Holmgaard et al.   Journal for ImmunoTherapy of Cancer

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

(2018) Davide Melisi et al.   BRITISH JOURNAL OF CANCER

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies

(2018) James J Harding et al.   CLINICAL CANCER RESEARCH

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

(2017) Jonathan M. Yingling et al.   Oncotarget

Limited role for transforming growth factor–β pathway activation-mediated escape from VEGF inhibition in murine glioma models

(2016) Davide Mangani et al.   NEURO-ONCOLOGY

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

(2015) Andrew X Zhu et al.   LANCET ONCOLOGY

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients

(2015) Maria Serova et al.   Oncotarget

Treating advanced hepatocellular carcinoma: How to get out of first gear

(2014) James J. Harding et al.   CANCER

Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

(2013) Ivelina Gueorguieva et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II

(2013) Francesco Dituri et al.   PLoS One

Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma

(2009) Y. Hoshida et al.   CANCER RESEARCH

VEGF and inhibitors of TGF  type-I receptor kinase synergistically promote blood-vessel formation by inducing  5-integrin expression

(2009) Z. Liu et al.   JOURNAL OF CELL SCIENCE

TGFβ in Cancer

(2008) Joan Massagué   CELL

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE